<article id="sc_page07" class="slide" data-ag-slide-name="sc_page07">
    <div class="basic">
        <div id="summary_main_bg2" class="main_content_style">
            <h1 data-ag-editable="Key Messages Main Title">From the first and throughout all cycles, with Neulasta<sup>®</sup>
                you achieve<sup>1-6</sup></h1>
            <ul data-ag-editable="Key Messages Main List">
                <li>
                    Highly efficient and efficacious help in protecting your patients from febrile neutropenia

                </li>
               <li>Thereby helping to achieve a more successful chemotherapy delivery through dose maintenance
               </li>
            </ul>
            <div id="vaccine_img" data-ag-editable="Key Messages Vaccine HTML">
                <img data-ag-editable="Key Messages Vaccine Image" src="content/images/carer_pages/summary_page_bg.png">
            </div>
        </div>
    </div>
    <div class="lightbox_data" id="key_messages_refs" style="display: none;">
        <div class="main_content_style">
            <p>
                <strong data-ag-editable="Key Messages References Title">References:</strong>
            </p>
            <div data-ag-editable="Key Messages References List">
                <ol>
                    <li>von Minckwitz G, <em>et al.</em> Eur J Cancer 2009;45:608-617.</li>
                    <li>Aapro M, <em>et al.</em> Crit Rev Oncol Hematol 2010;74(3):203-10.</li>
                    <li>Leonard R, <em>et al.</em> Eur J Cancer Suppl 2009:7(2):270#PD5033.</li>
                    <li>Borget I, <em>et al.</em> EJHP Practice 2009;15,58-61.</li>
                </ol>
            </div>
        </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="sc_page07_refs">
        <div class="main_content_style">
            <p><strong data-ag-editable="References Title">References:</strong></p>
            <br />
            <div data-ag-editable="References List">
                <ol>
                    <li>Cooper KL et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 23(11):404</li>
                    <li>Neulasta<sup>®</sup>, Summary of Product Characteristics</li>
                    <li>Mey U et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Cancer Care 2007; 15(7):877-884</li>
                    <li>Johnston E et al. Randomized, Dose-Escalation Study of SD/01 Compared With Daily Filgrastim in Patients Receiving Chemotherapy. J Clin Oncol 2000; 18(13):2522-2528</li>
                    <li>Leonard R et al. Secondary prophylaxis with G-CSF has a major effect on delivered dose intensity: The results of the UK NCRI/Anglo Celtic SPROG trial for adjuvant chemotherapy of breast cancer. Eur J Cancer Suppl 2009; 7(2):270</li>
                    <li>Aarts M et al. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 2013; 31(34):4290-4296</li>
                </ol>
            </div>
            <p data-ag-editable="References Bottom Copy"></p>
        </div>
    </div>
    <!-- Reference Information Ends -->

    </article>